following a resubmission
drospirenone/ethinylestradiol (Yasmin®) is not recommended for use within NHS Scotland.
Indication under review: oral contraception.
Drospirenone/ethinylestradiol has been shown to have similar contraceptive effectiveness to other combined oral contraceptives in routine use, with no significant differences in adverse event profile.
The manufacturer did not present a sufficiently robust economic case to gain acceptance by SMC.
Download detailed advice121KB (PDF)
- Medicine name:
- ethinylestradiol with drosperinone (Yasmin)
- SMC ID:
- Oral contraception
- Pharmaceutical company
- Bayer plc/Bayer Schering Pharma
- BNF chapter
- Obstetrics, gynaecology, and urinary-tract disorders
- Submission type
- Not recommended
- Date advice published
- 11 April 2011